Standard BioTools reports preliminary FY2023 rev $106M; merger closed Jan 5, combined cash >$550M

STANDARD BIOTOOLS INC.

2023-FY EPS reported -$0.94 revenue$106,340,000

Preliminary Q4 2023 revenue ~$28M and full year ~$106M for Standard BioTools.
SomaLogic preliminary Q4 revenue ~$23M and full year ~$86M.
Core revenue grew >10% YoY; instrument revenue grew >40% YoY.
Merger with SomaLogic completed Jan 5, 2024; combined cash >$550M as of Dec 31, 2023.
Company to report full Q4 and FY2023 results in early March with 2024 outlook.

item 2.02 item 7.01 item 9.01

Key facts

Extracted from this filing and checked against the source text.

Earnings Releases SEC 8-K Item 2.02 confidence 0.95

STANDARD BIOTOOLS INC. reported fourth quarter 2023 results: revenue approximately $28 million.

Period: fourth quarter 2023
Revenue: approximately $28 million
Result: preliminary results

Exact text from the filing

Standard BioTools expects fourth quarter 2023 revenue of approximately $28 million

View on SEC.gov

Earnings Releases SEC 8-K Item 2.02 confidence 0.95

STANDARD BIOTOOLS INC. reported full year 2023 results: revenue approximately $106 million.

Period: full year 2023
Revenue: approximately $106 million
Result: preliminary results

Exact text from the filing

full year 2023 revenue of approximately $106 million

View on SEC.gov

Browse all earnings releases →

STANDARD BIOTOOLS INC. filing history →

Source: SEC EDGAR

accession 0001104659-24-002092

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.